Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eton Pharmaceuticals (ETON) Change in Accured Expenses: 2019-2025

Historic Change in Accured Expenses for Eton Pharmaceuticals (ETON) over the last 7 years, with Sep 2025 value amounting to $1.8 million.

  • Eton Pharmaceuticals' Change in Accured Expenses rose 211.15% to $1.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.6 million, marking a year-over-year increase of 222.45%. This contributed to the annual value of $1.5 million for FY2024, which is 40.09% down from last year.
  • Per Eton Pharmaceuticals' latest filing, its Change in Accured Expenses stood at $1.8 million for Q3 2025, which was up 938.37% from $172,000 recorded in Q2 2025.
  • Over the past 5 years, Eton Pharmaceuticals' Change in Accured Expenses peaked at $2.0 million during Q4 2024, and registered a low of -$1.6 million during Q1 2024.
  • Its 3-year average for Change in Accured Expenses is $413,273, with a median of $574,000 in 2024.
  • As far as peak fluctuations go, Eton Pharmaceuticals' Change in Accured Expenses skyrocketed by 4,230.00% in 2023, and later plummeted by 232.28% in 2024.
  • Eton Pharmaceuticals' Change in Accured Expenses (Quarterly) stood at $120,000 in 2021, then plummeted by 153.33% to -$64,000 in 2022, then skyrocketed by 2,246.88% to $1.4 million in 2023, then skyrocketed by 48.69% to $2.0 million in 2024, then soared by 211.15% to $1.8 million in 2025.
  • Its Change in Accured Expenses stands at $1.8 million for Q3 2025, versus $172,000 for Q2 2025 and -$1.4 million for Q1 2025.